ClinicalTrials.gov
ClinicalTrials.gov Menu

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03506477
Recruitment Status : Recruiting
First Posted : April 24, 2018
Last Update Posted : June 12, 2018
Sponsor:
Information provided by (Responsible Party):
Andrew Alexis, MD, Icahn School of Medicine at Mount Sinai

Brief Summary:
This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques in skin of color (and its change with Enstilar ® treatment) as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Psoriasis Drug: Enstilar® foam Drug: Vehicle foam Phase 4

Detailed Description:

Psoriasis is a chronic inflammatory disorder primarily affecting the skin and joints. This condition occurs in different ethnic groups worldwide with varying prevalence.

There are notable differences in psoriasis presentation in skin of color groups. Black patients with psoriasis tend to have less erythema, increased risk of pigmentation, thicker plaques, more scaling, and greater body involvement as compared to white patients. The resolution of psoriasis lesions in darker skin types is associated with a higher rate of dyspigmentation (both hyper- and hypo-pigmentation), which may be more bothersome to patients than the psoriasis itself. Further, several studies have shown that psoriasis is associated with greater psychological impact and worse quality of life in non-whites with psoriasis compared to whites.

Unique issues in skin of color populations make studies dedicated to darker skin types essential for the treatment of psoriasis in these populations. This study will evaluate the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in darker skin types. This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life in skin of color.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: 4:1 Enstilar(R): placebo from baseline to week 4, then open-label Enstilar from weeks 4 to 8.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double-blind, vehicle-controlled from week 0 to 4
Primary Purpose: Treatment
Official Title: A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color
Actual Study Start Date : May 21, 2018
Estimated Primary Completion Date : April 30, 2019
Estimated Study Completion Date : May 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Enstilar® foam
Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
Drug: Enstilar® foam
for 4 weeks
Other Name: Enstilar 0.005%-0.064% Topical Foam

Placebo Comparator: Vehicle foam
does not contain the active ingredient
Drug: Vehicle foam
for 4 weeks




Primary Outcome Measures :
  1. Proportion of patients who achieved treatment success [ Time Frame: Week 4 ]
    Proportion of patients at week 4 who achieved treatment success according to Investigator Global Assessment (IGA mod 2011) of the entire body including scalp. IGA will range from 0 (clear) to 4 (severe). Treatment success is defined as IGA of clear (0) or almost clear (1) for patients with ≥ moderate disease at baseline or IGA of clear (0) for patients with mild disease at baseline.


Secondary Outcome Measures :
  1. Change in Psoriasis Area and Severity Index (PASI) [ Time Frame: baseline, 4 weeks, 8 weeks ]
    Proportion of patients achieving ≥50% improvement and/or ≥75% improvement in PASI at weeks 4 and 8 compared to baseline. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease)

  2. Change in Psoriasis Scalp Severity Index [ Time Frame: baseline, 2 weeks, 4 weeks, 8 weeks ]
    Proportion of patients achieving ≥50% improvement and/or ≥75% improvement in PSSI at weeks 2, 4 and 8 compared to baseline if applicable. The Psoriasis Scalp Severity Index (PSSI) assesses severity of scalp disease along the parameters of erythema, induration, and desquamation. The PSSI uses a 5-point scale to grade the three aforementioned clinical parameters. The parameters scores are summed and multiplied by an integer (0-6) that represents the area of affected scalp. The PSSI score ranges from 0 (no disease) to 72 (maximal disease).

  3. Investigator Global Assessment (IGA mod 2011) [ Time Frame: at week 8 ]
    Proportion of patients at week 8 who achieved treatment success according to IGA mod 2011 of the entire body including scalp. IGA will range from 0 (clear) to 4 (severe). Treatment success is defined as IGA of clear (0) or almost clear (1) for patients with ≥ moderate disease at baseline or IGA of clear (0) for patients with mild disease at baseline.

  4. Change in Scalp Investigator Global Assessment (ScIGA) [ Time Frame: baseline, 4 weeks, 8 weeks ]
    Proportion of patients at weeks 4 and 8 who achieved treatment success according to ScIGA. ScIGA will range from 0 (clear) to 4 (severe). Treatment success is defined as ScIGA of clear (0) or almost clear (1) for patients with ≥ moderate disease at baseline or ScIGA of clear (0) for patients with mild disease at baseline.

  5. Change in Patient's Global Assessment of Itch [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]
    Patient's Global Assessment of Itch as compared to baseline will be measured by Visual Analog Scale (VAS). The VAS is a numerical scale used to assess patients' perception of pruritus/itch.The evaluation is a 10cm long line on which the subjects indicate the severity of their pruritus from "0" (no pruritus) to "10" (severe pruritus).

  6. Patient's Global Assessment of disease severity (PaGA) [ Time Frame: Baseline, 4 weeks, 8 weeks ]
    PaGA compared to baseline, will have 5 distinct options ranging from (0) "Clear" to (4) "Severe." Treatment response will be defined as clear or almost clear disease (for those with moderate or severe disease at baseline) or clear disease (for those with mild disease at baseline).

  7. Change in erythema indices of target psoriasis plaque [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]
    A skin spectrophotometer (Mexameter) will be used to quantify the degree of erythema of lesional skin compared to an index area (of unaffected skin), compared to baseline

  8. Change in melanin indices of target psoriasis plaque [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]
    A skin spectrophotometer (Mexameter) will be used to quantify the melanin index (degree of hyperpigmentation or hypopigmentation) of lesional skin compared to an index area of unaffected skin, compared to baseline

  9. Change in physician dyspigmentation visual analog scale (VAS) [ Time Frame: baseline, 4 weeks, 8 weeks ]
    An investigator will perform a visual analog scale (VAS) rating the degree of dyspigmentation of the skin. This VAS will range from - 5 to 5 as follows: 5 severe dark brown pigmentation (darkest imaginable color), 4 dark brown pigmentation, 3 medium brown pigmentation, 2 light brown pigmentation, 1 slight dark pigmentation (barely perceptible compared to surrounding skin), 0 baseline skin pigmentation, -1 slight hypopigmentation (barely perceptible compared to surrounding skin), -2 mild hypopigmentation (light brown), -3 moderate hypopigmentation (creme-colored skin), -4 severe hypopigmentation (almost complete absence of pigment), -5 depigmentation (complete absence of pigment), compared to baseline

  10. Change from baseline in Dermatology Life Quality Index (DLQI) [ Time Frame: Baseline, 2 weeks, 4 weeks, 8 weeks ]
    DLQI full scale is from 0 (no effect at all on patient's life) to 30 (extremely large effect on patients' life compared to baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written, signed and dated informed consent prior to initiating any study-related activities.
  • Male or female >18 years of age at the time of screening
  • Fitzpatrick Skin phototype IV-VI, non-white race/ethnicity, including but not limited to - --African Americans, Asians, Pacific Islanders and Hispanics.
  • Clinical diagnosis of chronic plaque-type psoriasis of the body
  • Plaque psoriasis with ≥2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score ≥ 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4)
  • Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d
  • Must be in general good health as judged by the Investigator, based on medical history and physical examination.

Exclusion Criteria:

  • Form of diagnosed psoriasis other than chronic plaque psoriasis (i.e. guttate, erythrodermic, pustular)
  • Diagnosis of other active, ongoing skin diseases or skin infections that may interfere with examination of psoriasis lesions
  • Ongoing use of other psoriasis treatment including but not limited to topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy. The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies
  • Use of oral estrogen therapy, excluding oral contraceptive pills
  • Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception.
  • Patients unwilling to limit exposure to UV light
  • Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk
  • Patients with disorders of calcium metabolism and/or hypercalcemia
  • Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)
  • History of allergy to any component of the IP

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03506477


Locations
United States, New York
Mount Sinai West Recruiting
New York, New York, United States, 10023
Contact: Ingrid Sanabria-Gonzalez    212-523-3812    Ingrid.Sanabria@mountsinai.org   
Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Investigators
Principal Investigator: Andrew Alexis, MD, MPH Icahn School of Medicine at Mount Sinai

Responsible Party: Andrew Alexis, MD, Chair, Department of Dermatology, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT03506477     History of Changes
Other Study ID Numbers: GCO 17-2468
HSM# 17-05032 ( Other Identifier: Icahn School of Medicine at Mount Sinai )
First Posted: April 24, 2018    Key Record Dates
Last Update Posted: June 12, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: With Leo, Pharma.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Andrew Alexis, MD, Icahn School of Medicine at Mount Sinai:
skin of color
psoriasis
Enstilar
skin diseases

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone
Betamethasone Valerate
Betamethasone sodium phosphate
Calcipotriene
Calcitriol
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Vitamins
Micronutrients
Growth Substances
Bone Density Conservation Agents